Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hazel Morrison

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Tuberculosis (Edinburgh, Scotland)|June 15, 2024
Evaluation of immune profiles associated with control of mycobacterial growth in systemic lupus erythematosus (SLE) patientsJomkwan Ongarj, Porntip Intapiboon, Smonrapat Surasombatpattana, et al.
Cell Reports. Medicine|May 21, 2026
Lung mucosal and systemic responses at single-cell resolution in an aerosolized Mycobacterium bovis BCG human challenge modelShuailin Li, Hazel Morrison, Mihaela Duta, et al.
Frontiers in Immunology|November 29, 2024
A dose escalation study to evaluate the safety of an aerosol BCG infection in previously BCG-vaccinated healthy human UK adultsTimothy Fredsgaard-Jones, Stephanie A Harris, Hazel Morrison, et al.
The Lancet. Infectious Diseases|November 28, 2023
Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trialAnne Wajja, Beatrice Nassanga, Agnes Natukunda, et al.
The Lancet. Infectious Diseases|January 6, 2024
Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis controlAnne Wajja, Beatrice Nassanga, Agnes Natukunda, et al.
Clinical and Translational Science|October 20, 2021
Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trialSusanne H Hodgson, Poppy Iveson, Jessica Larwood, et al.
Nature Communications|May 29, 2025
Early mucosal responses following a randomised controlled human inhaled infection with attenuated Mycobacterium bovis BCGJulia L Marshall, Iman Satti, Mirvat Surakhy, et al.
The Lancet. Infectious Diseases|April 15, 2024
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trialIman Satti, Julia L Marshall, Stephanie A Harris, et al.
The Lancet. Microbe|May 4, 2024
Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection studySusan Jackson, Julia L Marshall, Andrew Mawer, et al.
Lancet (London, England)|December 11, 2020
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKMerryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Tuberculosis (Edinburgh, Scotland)|June 15, 2024
Evaluation of immune profiles associated with control of mycobacterial growth in systemic lupus erythematosus (SLE) patientsJomkwan Ongarj, Porntip Intapiboon, Smonrapat Surasombatpattana, et al.
Cell Reports. Medicine|May 21, 2026
Lung mucosal and systemic responses at single-cell resolution in an aerosolized Mycobacterium bovis BCG human challenge modelShuailin Li, Hazel Morrison, Mihaela Duta, et al.
Frontiers in Immunology|November 29, 2024
A dose escalation study to evaluate the safety of an aerosol BCG infection in previously BCG-vaccinated healthy human UK adultsTimothy Fredsgaard-Jones, Stephanie A Harris, Hazel Morrison, et al.
The Lancet. Infectious Diseases|November 28, 2023
Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trialAnne Wajja, Beatrice Nassanga, Agnes Natukunda, et al.
The Lancet. Infectious Diseases|January 6, 2024
Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis controlAnne Wajja, Beatrice Nassanga, Agnes Natukunda, et al.
Clinical and Translational Science|October 20, 2021
Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trialSusanne H Hodgson, Poppy Iveson, Jessica Larwood, et al.
Nature Communications|May 29, 2025
Early mucosal responses following a randomised controlled human inhaled infection with attenuated Mycobacterium bovis BCGJulia L Marshall, Iman Satti, Mirvat Surakhy, et al.
The Lancet. Infectious Diseases|April 15, 2024
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trialIman Satti, Julia L Marshall, Stephanie A Harris, et al.
The Lancet. Microbe|May 4, 2024
Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection studySusan Jackson, Julia L Marshall, Andrew Mawer, et al.
Lancet (London, England)|December 11, 2020
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKMerryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, et al.
Pageof 2